Related Experiment Videos

Simvastatin does not normalize very long chain fatty acids in adrenoleukodystrophy mice

N Cartier1, S Guidoux, F Rocchiccioli

  • 1Inserm U342, Hôpital Saint-Vincent de Paul, 82 avenue Denfert Rochereau, 75014, Paris, France. cartier@cochin.inserm.fr

FEBS Letters
|August 10, 2000
PubMed

Insights

Simvastatin, a statin drug, did not reduce very long chain fatty acids (VLCFAs) in X-linked adrenoleukodystrophy (ALD) mouse models. Instead, high doses significantly increased VLCFA levels in the brain, suggesting potential risks.

Area of Science:

  • Biochemistry
  • Genetics
  • Neuroscience

Background:

  • X-linked adrenoleukodystrophy (ALD) is a genetic disorder causing demyelination due to very long chain fatty acid (VLCFA) accumulation.
  • Lovastatin, a HMG-CoA reductase inhibitor, has shown potential in normalizing VLCFA levels in ALD patient cells and plasma.

Purpose of the Study:

  • To investigate the efficacy of simvastatin, a lovastatin analog, in reducing VLCFA accumulation in an ALD mouse model.
  • To assess the impact of simvastatin treatment on VLCFA levels in various tissues, particularly the brain, of ALD mice.

Main Methods:

  • X-linked adrenoleukodystrophy (ALD) mice were administered simvastatin (20 or 60 mg/kg/day) orally for 6-12 weeks.
  • VLCFA content was measured in mouse tissues, including the brain, to evaluate the drug's effect.

Main Results:

  • Simvastatin treatment did not lead to a decrease in VLCFA content in any tested tissues of ALD mice.
  • A significant increase in brain VLCFA levels was observed in ALD mice treated with the higher dose (60 mg/kg/day) of simvastatin.

Conclusions:

  • Simvastatin is ineffective in reducing VLCFA accumulation in the tissues of an ALD mouse model.
  • High-dose simvastatin may exacerbate VLCFA accumulation in the brain of ALD mice, indicating potential adverse effects.

Related Concept Videos